Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
transports lactic acid and other monocarboxylic acids. Additionally we are shipping Malignant T Cell Amplified Sequence 1 Proteins (10) and Malignant T Cell Amplified Sequence 1 Kits (6) and many more products for this protein.
Showing 10 out of 64 products:
Human Polyclonal MCTS1 Primary Antibody for EIA, WB - ABIN453186
Kasiappan, Shih, Chu, Chen, Liu, Huang, Choy, Shu, Din, Chu, Hsu: Loss of p53 and MCT-1 overexpression synergistically promote chromosome instability and tumorigenicity. in Molecular cancer research : MCR 2009
Show all 3 references for ABIN453186
Chicken Polyclonal MCTS1 Primary Antibody for WB - ABIN2779047
Shi, Levenson, Gartenhaus: Identification and characterization of a novel enhancer for the human MCT-1 oncogene promoter. in Journal of cellular biochemistry 2003
This study demonstrated that MCT1 was up regulation in ipsilateral site of brain afeter cerebral ischemia.
The soleus, liver and heart were the main tissues that showed improved the MCT1 mRNA expression, indicating its important role in controlling MLSS concentration in mice.
Exercise-induced changes in tumour LDH-B (show LDHB Antibodies) and MCT1 expression are modulated by oestrogen-related receptor alpha in breast cancer-bearing BALB/c mice
Chronic lactate administration after exercise increases MCT1 protein expression, which can be involved in the regulation of the observed increase in muscle glycogen (show GYS1 Antibodies) storage after exercise training.
This study showed that mouse MCT1, MCT2 (show SLC16A7 Antibodies), and MCT4 (show SLC16A3 Antibodies) are expressed in the PNS. While DRG neurons express MCT1, myelinating Schwann cells.
These data for the first time demonstrate that MCT1 is critical for regeneration of both sensory and motor axons in mice following sciatic nerve crush
Study demonstrated that PTEN (show PTEN Antibodies) loss and MCT-1 induction synergistically promoted the neoplastic multinucleation via the Src (show SRC Antibodies)/p190B (show ARHGAP5 Antibodies) signaling activation.
in Parkinson's disease, the levels of MCT1, MCT2 (show SLC16A7 Antibodies) and GLUT1 (show SLC2A1 Antibodies) is not changed following dopaminergic neurodegeneration
results suggest that a reduction in mitochondria is a result, rather than the cause, of the metabolic deficiency observed in Basigin-null mice, and likely occurs because of reduced metabolic activity in the absence of MCT1 expression.
miR (show MLXIP Antibodies)-29a, miR (show MLXIP Antibodies)-29b selectively target MCT1 3'UTR (show UTS2R Antibodies) ; the miR (show MLXIP Antibodies)-29 isoforms are highly expressed in islets and contribute to silencing Mct1 in beta cells; miR (show MLXIP Antibodies)-29 isoforms contribute to beta-cell-specific silencing of the MCT1 transporter and may affect insulin (show INS Antibodies) release
MCT1 (show CMA1 Antibodies) expression was not clearly associated with overall or disease-free survival. MCT4 (show SLC16A4 Antibodies) and CD147 expression correlate with worse prognosis across many cancer types. These results warrant further investigation of these associations.
MCT1 (show CMA1 Antibodies) and GLUT1 (show SLC2A1 Antibodies) may be potential prognostic markers in adenocarcinoma.
MCT1 (show CMA1 Antibodies) is highly expressed in anaplastic thyroid cancer compared to non-cancerous thyroid tissue and papillary thyroid cancer.
interaction of rmEMMPRINex with U937 cells leads to inhibition of MCT1 (show CMA1 Antibodies) membrane expression, intracellular activation of procaspase-9, followed by DNA fragmentation and apoptosis.
Down regulation of MCT1 (show CMA1 Antibodies) promote the sensitivity to cisplatin in ovarian cancer cells. This effect appeared to be mediated by antagonizing Fas (show FAS Antibodies).
The possible cooperative role of CD147 and MCT1 (show CMA1 Antibodies) in determining cisplatin resistance.
The first IF method has been developed and optimised for detection of MCT 1 (show CMA1 Antibodies) and MCT4 (show SLC16A4 Antibodies) in cancer patient circulating tumour cells
CD147 interacts with MCT1 (show CMA1 Antibodies) to regulate tumor cell glycolysis, resulting in the progression of thyroid carcinoma.
MCT1 (show CMA1 Antibodies) was up-regulated by exposure to DL-2-hydroxy-(4-methylthio)butanoic acid(HMTBA). Moreover, total monolayer MCT1 (show CMA1 Antibodies) immunoreactivity increased 1.8-fold in HMTBA-supplemented cultures, this effect mainly being localised at the apical membrane.
Our findings suggest that SNPs in MCT1 (show CMA1 Antibodies) and MCT2 (show SLC16A7 Antibodies) genes may affect clinical outcomes and can be used to predict the response to adjuvant chemotherapy in NSCLC patients who received surgical treatment once validated in future study.
Data indicate that monocarboxylate transporters (MCTs1-4) were all found to be expressed in brains of embryos, and were localized in both neurons and astrocyte.
This study confirmed age-dependent changes of MCT1 expression in the rumen epithelium of newborn calves and showed that its expression might be affected by liquid feed type.
These findings show that MCT 1 increases with the development of rumen function and also in adult animals MCT 1 may change with the feeding.
The expression and distribution of monocarboxylate transporter 1 along the gastrointestinal tract of calves suggest it may play a role in transport of short chain fatty acids and their metabolites.
The results show that monocarboxylate transporter 1 (MCT1) is a major route for short chain fatty acids (SCFA) efflux across the basolateral membrane of bovine large intestine and that it could play a role in the regulation of intracellular pH.
Data suggest that expression of MCT1 in intestinal mucosa can be altered by diet; here, expression of MCT1 is down-regulated in colonic mucosa by high-protein diet and appears to be linked to fermentation of dietary proteins by intestinal microbes.
MCT1-mRNA showed a higher expression in the ileum; feeding inulin-coated butyrate resulted in an increased ileal surface; delivery of butyrate to the colon requires a more resistant inulin-coating.
The protein encoded by this gene is a proton-linked monocarboxylate transporter that catalyzes the movement of many monocarboxylates, such as lactate and pyruvate, across the plasma membrane. Mutations in this gene are associated with erythrocyte lactate transporter defect. Alternatively spliced transcript variants have been found for this gene.
malignant T cell amplified sequence 1
, malignant T cell-amplified sequence 1
, malignant T-cell-amplified sequence 1
, multiple copies T-cell malignancies
, multiple copies T-cell malignancies 1
, Malignant T cell amplified sequence 1-A
, malignant T cell-amplified sequence 1-A
, malignant T-cell-amplified sequence 1-A
, MCT 1
, monocarboxylate transporter 1
, solute carrier family 16 (monocarboxylic acid transporters), member 1
, solute carrier family 16 member 1
, solute carrier family 16, member 1 (monocarboxylic acid transporter 1)
, solute carrier 16 (monocarboxylic acid transporter), member 1
, monocarboxylate transporter 1a